Skinnavi uses ultrasound to measure the firmness and thickness of skin for noninvasive and instant quantification of the skin's mechanical properties. These data can be used to better quantify how medical conditions, products, and procedures affect the skin.

Research

In addition to its applications in clinical dermatology, MicroElastic's technology is being explored for multiple medical applications in collaboration with academic researchers.

Chronic Graft-Versus-Host-Disease

Towards a new standard in GVHD care

MicroElastic and Duke Health have been awarded a Phase II Small Business Technology Transfer (STTR) grant to investigate the use of Bullseye technology in the management of Chronic Graft-Versus-Host-Disease (cGVHD).

For patients undergoing hematopoietic stem cell transplantation for blood cancer treatment, there is a 70% chance of developing cGVHD, a deadly condition without a cure. cGVHD manifests in the skin as sclerosis, providing a potential biomarker to detect the disease and manage treatment. However, current methods – manual palpitation, compression, suction – are imprecise and exhibit too much inter-provider variability to be clinically useful. Our Bullseye technology takes quantitative measurements of skin elasticity that can help facilitate earlier detection of cGVHD, track disease progression, characterize an individual's response to therapy, and assist in the clinical assessment of skin.*

Lymphedema

Skin elasticity as a biomarker for lymphedema

MicroElastic was awarded a Small Business Innovation Research (SBIR) grant to investigate the use of Bullseye technology in the management of lymphedema. We are collaborating with the Duke Cancer Center on this research.

Lymphedema is a condition caused by a blockage in the lymphatic system. Lymphedema results in swelling and pressure buildup in surrounding tissue that stretches the overlying skin. The tightness of the streching can be directly measured by Bullseye technology and serve as a potential biomarker for lymphedema. By enabling convenient and precise quantification of lymphedema using skin elasticity as a biomarker, Bullseye technology can improve long-term outcomes, enhance patient compliance, and help clinicians better detect and manage lymphedema overall.*

*This statement has not been evaluated by the FDA, and Bullseye is not cleared for sale in the USA or intended for clinical diagnostic use.

Team

Peter Hollender, Ph.D.

Founder & Chief Executive Officer
Director

Ultrasound expert, passionate innovator. Founded MicroElastic to deliver customer-focused technology solutions to enable precision medicine.

Thomas Hitchcock, Ph.D.

Strategic Advisor
Director

Co-founder of Xycrobe and Bellus (both sold to Crown Labs)

Petek Sener, MEng.

Ultrasound Engineer

Biomedical engineer, device software lead, clinical research coordinator.

Experienced Contractors and Advisors

Steve Grenon

Quality and Product Development Advisor

Rich McGivney, CPA

Chief Financial Officer

William F. Walker, Ph.D.

Ultrasonics and Commercialization Advisor

Matt Norwood

Sales Strategy Advisor

Fred Kornharens

Business Advisor

Jesko von Windheim, Ph.D., MBA.

Business Advisor

Nick Bottenus, Ph.D.

Scientific Advisor

Mark Palmeri, M.D., Ph.D.

Co-Inventor and Chief Scientific Advisor

Suyash Kumar

Software Advisor

Adela Rambi Cardones, M.D.

Dermatologist and Medical Advisor

News and Updates

September 10th, 2021

MicroElastic continues collaborating with Lumedica on an SBIR-funded project to develop an integrated elastography scanner. The integrated device combines Lumedica’s deep imaging Optical Coherence Tomography (OCT) scanner with our Bullseye system to create the first Optical Coherence Elastography-CSI (OCE-CSI) system for dermatologic applications.

September 5th, 2021

MicroElastic was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). With this grant, we will investigate the use of our Bullseye technology to study clinical lymphedema in collaboration with the Duke Cancer Center.

For patients undergoing lymph node dissection and/or radiation therapy for cancer treatment, developing lymphedema is a lifetime risk. Lyhmphedema is a lifeling condition without a cure and causes swelling of the extremities and motor impairment. According to the 2016 Consensus Document of the International Society of Lymphology, “An accurate diagnosis of lymphedema is essential for appropriate therapy”. Detecting and monitoring lymphedema is critical to successful long term management, but current methods lack the required precision, repeatability, and convenience to detect the disease before symptoms present. Our Bullseye technology measures skin elasticity instantly and noninvasively and can provide a useful, objective measure for quantifying the disease in a clinical setting.

NIH's SBIR/STTR program funds startups that create products and services that can potentially benefit society. A group of technical and commercial experts evaluates each application, provides feedback, and assesses the technical and commercial merit of the proposed technology. After the company is awarded a Phase I grant (up to $256,000), it can apply for a Phase II grant (up to $1,000,000) to further develop and commercialize its technology.
To learn more visit: https://sbir.nih.gov/

June 18th, 2021

MicroElastic welcomes Thomas Hitchcock, PhD. as a new board member and strategic advisor. Dr. Hitchcock has founded Xycrobe and Bellus which were both sold to Crown Labs. We are excited for the unique industry-specific perspective and vision he will be bringing to our team.

January 29th, 2021

MicroElastic has achieved its most important commercial validation to date, by fully committing its entire fleet of demo devices to clinical studies with strategic partners. The initial engagements will last several months and will yield important evidence for the utility of our technology in the context of anti-aging applications.

October 5th, 2020

Our STTR-funded clinical study is now underway at Duke Health. This study will both build a baseline normagram of skin elasticity in healthy volunteers, and correlate our noninvasive measurements of elasticity against invasive gold-standard scoring of skin sclerosis via biopsy in patients with sclerotic skin disease, in particular patients with Graft-Versus-Host-Disease.

July 29th, 2020

MicroElastic is excited to announce that we are launching a demo fleet of Bullseye devices in September. We are currently arranging clinical studies with partners in the skincare industry to evaluate the effects of several therapies on skin elasticity. Please contact us if you are interested in a virtual demo!

January 24th, 2020

MicroElastic will be attending the American Academy of Dermatology Annual Meeting to share updates on our technology and clinical data, as well as engage with potential strategic partners. Please reach out directly if you are attending and would like to arrange a meeting. The event will be held March 20-24 at the Colorado Convention Center in Denver, CO.

January 14th, 2020

MicroElastic was invited to deliver a 4-minute pitch presentation at the Venture Connect Summit, hosted by the Council for Entrepreneurial Development, and considered the premier life science event in the southeast. The event will be held March 17-19 at the Raleigh Convention Center in Raleigh, NC.

Contact Us

For general inquiries, please email info@microelastic.com

MicroElastic is always interested in exceptional talent. To inquire about joining the team, please email jobs@microelastic.com

NOTICE: The products described on this website are not cleared in the USA and are not intended for clinical diagnostic use.
© MicroElastic Ultrasound Systems, All Rights Reserved.